Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.38 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.37 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 2/20 | 0.37 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.36 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1643268 | 0.86 | LMNA (0.42) | LMNAALDH1A1PPARGNPC1WDR5 | |
| SCHEMBL1285393 | 0.84 | CSNK1D (0.37) | LMNAALDH1A1PPARGS1PR1S1PR3 | |
| SCHEMBL1644070 | 0.84 | PDE2A (0.38) | LMNAALDH1A1PPARGWDR5MAPK1 | |
| SCHEMBL1643189 | 0.83 | WDR5 (0.36) | LMNAALDH1A1PPARGNPC1WDR5 | |
| SCHEMBL1644603 | 0.82 | MEN1 (0.37) | LMNAALDH1A1NPC1KMT2AMEN1 | |
| SCHEMBL1644704 | 0.81 | BRPF1 (0.34) | LMNAALDH1A1PPARGS1PR1S1PR3 | |
| SCHEMBL1644611 | 0.80 | HPGDS (0.46) | LMNAALDH1A1MAPK1RPS6KA1 | |
| SCHEMBL1644380 | 0.77 | PDE2A (0.41) | KMT2AMEN1 | |
| SCHEMBL1643127 | 0.77 | PDE2A (0.45) | — | |
| SCHEMBL1645206 | 0.76 | HPGDS (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | LMNA 2439/4885ALDH1A1 1265/4885PPARG 376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.